Lunit
Healthcare Software · South Korea · 201-500 Employees
View Company Info for Free
Overview
Headquarters
27 Teheran-ro 2-gil 15 Fl, Gangnam-gu, S...Website
www.lunit.ioRevenue
$58.8 MillionStock Symbol
328130.KQIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
3
4
2
2
About Lunit
With AI, Lunit aims to make data-driven medicine the new standard of care. We are especially focused on conquering cancer, one of the leading causes of death worldwide. We develop AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients.Explore more
Lunit Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lunit your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Lunit launches new products
Check out if Lunit is spiking on competitors!
Funding: Get notified immidiatlly once Lunit has new funding data
Check if Lunit has recently received funding, and reach out quickly before it becomes old news!
Click to see if Lunit had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Lunit
Earning: See what the market has to say on Lunit recently announced quarterly report
Lunit, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Lunit
Find 3 more new buyers
Company Profile Activity
Activity Insights
Lunit is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
Lunit is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about Lunit.
Lunit financials insights
Gather financial insights about Lunit, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$3.5M
2018
Series B
$15M
2021
Series C
$78M
Other Financing Round
$61M
2023
Other Financing Round
$150M
Lunit Tech Stack
A closer look at the technologies used by Lunit
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Lunit News & Media
Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better support treatment decision-making. SEOUL,...Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better support treatment decision-making. SEOUL, South Korea, April 18, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, presented six studies at the American Association for Cancer Research (AACLunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice
Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026 SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI. Lunit x LexingtonLunit, CellCarta Announce Strategic Collaboration to Accelerate AI-Enabled Digital Pathology for Companion Diagnostic Programs
Partnership combines Lunit's platform-agnostic AI pathology algorithms with CellCarta's global CDx development and laboratory execution to help biopharma teams de-risk assets and accelerate evidence generation and CDx launch pathways. SEOUL, South Korea and MONTREAL, March 30, 2026...
Read more news
Top Healthcare Software Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lunit
Sign Up For FreeTo access detailed company insights
With AI, Lunit aims to make data-driven medicine the new standard of care. We are especially focused on conquering cancer, one of the leading causes of death worldwide. We develop AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients.... Read More
